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ABSTRACT: Breast cancer is the most commonly diagnosed cancer and the second leading cause of cancer death in women.
Radioresistance remains one of the most critical barriers in radiation therapy for breast cancer. In this study, we employed a
parallel-reaction monitoring (PRM)-based targeted proteomic method to examine the reprogramming of the heat shock
proteome during the development of radioresistance in breast cancer. In particular, we investigated the diﬀerential expression of
heat shock proteins (HSPs) in two pairs of matched parental/radioresistant breast cancer cell lines. We were able to quantify 43
and 42 HSPs in the MCF-7 and MDA-MB-231 pairs of cell lines, respectively. By analyzing the commonly altered proteins, we
found that several members of the HSP70 and HSP40 subfamilies of HSPs exhibited substantially altered expression upon
development of radioresistance. Moreover, the expression of HSPB8 is markedly elevated in the radioresistant lines relative to
the parental MCF-7 and MDA-MB-231 cells. Together, our PRM-based targeted proteomics method revealed the
reprogramming of the heat shock proteome during the development of radioresistance in breast cancer cells and oﬀered
potential targets for sensitizing breast cancer cells toward radiation therapy.
■ INTRODUCTION
Breast cancer is the most common malignancy among women
and the second leading cause of cancer deaths in women in the
United States.1 Locoregional treatment of breast cancer with
radiation therapy has evolved over the past several decades,2
which has been a critical component of the multimodal
management of invasive breast cancer.3 However, development
of radioresistance becomes one of the most critical obstacles in
cancer radiotherapy.4,5 Therefore, identifying molecular targets
responsible for the radioresistant phenotype of breast cancer
cells is critical for enhancing the eﬃcacy of anti-cancer therapy
and for reducing the mortality of breast cancer patients.
Heat shock proteins (HSPs) are molecular chaperones which
bear important functions in protein folding/unfolding, cell cycle
regulation, and cellular protection against stress.6−8 HSPs have
been frequently shown to aﬀect disease progression. For
instance, HSP90, a molecular chaperone for protein folding
and client protein stabilization,9 is overexpressed in many types
of tumors and known to be associated with breast cancer
progression.10 Furthermore, some heat shock proteins, e.g.,
HSP257 and HSP27,8 were found to promote the development
of radioresistance in cancer cells. We reason that a systematic
assessment of how HSPs modulate the development of
radioresistance may lead to novel molecular targets for
sensitizing cancer cells to radiation therapy.
We recently developed a parallel-reactionmonitoring (PRM)-
based targeted proteomics method to examine the expression of
HSPs at the entire proteome scale.11 The method was
successfully employed to reveal the diﬀerentially expressed
HSPs during melanoma metastasis and led to the identiﬁcation
of DNAJB4 as a novel suppressor for melanoma metastasis.11
Here, we employed the PRM method to investigate
comprehensively the implications of HSPs in radioresistance
of breast cancer by proﬁling the diﬀerential expression of HSPs
in two pairs of matched wild-type (WT)/radioresistant breast
cancer cells (i.e., MCF-7 and MDA-MB-231 cells, and their
radioresistant counterparts).12,13 We quantiﬁed the expressions
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of 43 and 42 unique HSPs in the MCF-7 and MDA-MB-231
pairs, respectively. Our results support that HSP70, HSP40, and
HSPB8 proteins play important roles in radioresistance of breast
cancer cells.
■ MATERIALS AND METHODS
Generation of Radioresistant Breast Cancer Cell Lines.MCF-
7 cells were treated with a total of 60 Gy of γ rays to generate the
radioresistant clone (clone 6, referred as C6) and further exposed to an
additional term of 30 fractions of γ rays.12 Similarly, the radioresistant
clone (clone 5, referred as C5) of MDA-MB-231 cells was generated by
exposing the cells to a total dose of 30 Gy of ionizing radiation.13 The
radioresistant phenotype of the MCF-C6 and MDA-MB-231-C5 cells
was characterized by clonogenic survival assay, as reported
previously.12,13
Cell Culture. MCF-7 WT/radioresistant and MDA-MB-231 WT/
radioresistant cells were cultured in Dulbecco’s modiﬁed eagle medium
(DMEM). Culture media were supplemented with 10% fetal bovine
serum (Invitrogen, Carlsbad, CA) and penicillin (100 IU/mL). The
cells were maintained at 37 °C in a humidiﬁed atmosphere containing
5% CO2. Approximately 2 × 107 cells were harvested, washed with cold
PBS for three times, and lysed by incubating on ice for 30 min with
CelLytic M cell lysis reagent (Sigma) containing 1% protease inhibitor
cocktail. The cell lysates were centrifuged at 9000g at 4 °C for 30 min,
and the resulting supernatants were collected. For SILAC labeling
experiments, the cells were cultured in SILAC medium containing
unlabeled lysine and arginine, or [13C6,
15N2]-lysine and [
13C6]-arginine,
for at least ﬁve cell doublings.
Tryptic Digestion of Whole-Cell Protein Lysates. The whole-
cell lysates prepared from MCF-7 or MDA-MB-231 breast cancer cells
and their radioresistant counterparts were combined at 1:1 ratio,
incubated with 8M urea for protein denaturation, and then treated with
dithiothreitol and iodoacetamide for cysteine reduction and alkylation,
respectively. The proteins were subsequently digested with modiﬁed
MS-grade trypsin (Pierce) at an enzyme/substrate ratio of 1:100 in 50
mMNH4HCO3 (pH 8.5) at 37 °C overnight. The peptide mixture was
then dried in a Speed-vac, desalted with OMIX C18 pipet tips (Agilent
Technologies), and analyzed by LC-MS and MS/MS in the PRM
mode.
LC-PRM Analysis. All LC-PRM experiments were carried out on a
Q Exactive Plus quadrupole-Orbitrap mass spectrometer coupled with
an EASY-nLC 1200 system (Thermo Fishier Scientiﬁc). The samples
were automatically loaded onto a 4 cm trapping column (150 μm i.d.)
which was packed with ReproSil-Pur 120 C18-AQ resin (5 μm in
particle size and 120 Å in pore size, Dr. Maisch GmbHHPLC) at a ﬂow
rate of 3 μL/min. The trapping column was coupled to a 20 cm fused
silica analytical column (PicoTip Emitter, New Objective, 75 μm i.d.)
packed with ReproSil-Pur 120 C18-AQ resin (3 μm in particle size and
120 Å in pore size, Dr. Maisch GmbHHPLC). The peptides were then
separated using a 140 min linear gradient of 9−38% acetonitrile in 0.1%
formic acid and at ﬂow rate of 300 nL/min. The spray voltage was 1.8
kV. Peptide ions were collisionally activated in the HCD cell at a
normalized collision energy of 29 to yield MS/MS, which were
recorded in the Orbitrap analyzer at a resolution of 17 500 with an AGC
target of 1 × 105.
The linear predictor of empirical retention time (RT) from
normalized RT (iRT)14 for targeted peptides of HSPs was determined
by the linear regression of RTs of BSA standard peptides obtained for
the current chromatography setup.11,15,16 This RT−iRT linear
relationship was redeﬁned between every eight LC-MS/MS runs by
injecting another BSA tryptic digestion mixture. The targeted precursor
ions were monitored in scheduled PRM mode with an 8 min retention
time window.
All raw ﬁles were processed using Skyline (version 3.5) for the
generation of extracted-ion chromatograms and for peak integration.17
A total of 2−5 unique peptides with the highest abundances of
precursor ions were selected for the quantiﬁcation of each HSP. The 6
most abundant ions found in MS/MS acquired from shotgun
proteomic analysis were chosen for peptide identiﬁcation and
quantiﬁcation in PRM mode, where a mass accuracy of 20 ppm or
better was imposed for fragment ions during the identiﬁcation of
peptides in the Skyline platform. The targeted peptides were ﬁrst
manually checked to ensure that the chromatographic proﬁles of
multiple fragment ions derived from the light and heavy forms of the
same peptide could be overlaid. The data were then processed to ensure
that the distribution of the relative intensities of multiple transitions
associated with the same precursor ion is correlated with the theoretical
distribution in the MS/MS acquired from shotgun proteomic analysis.
The sum of peak areas from all transitions of light or heavy peptides was
used for quantiﬁcation.
TCGA Data, GEO Data, and Signaling Network Analysis.
Clinical data and mRNA expression proﬁles for the Molecular
Taxonomy of Breast Cancer International Consortium (META-
BRIC)18 cohort which contains 1982 breast cancer samples were
obtained from cBioPortal (http://www.cbioportal.org/data_sets.
jsp)19 and analyzed via its web-based Python API. The patients in
the METABRIC cohort were stratiﬁed based on with/without
radiotherapy, and we further stratiﬁed for those patients who received
radiotherapy based on median mRNA expressions of genes encoding
HSPs. Kaplan−Meier survival curves were generated to assess the
association between the mRNA expression of the HSP genes and
overall survival (OS) of breast cancer patients. p-values were generated
using log rank (Mantel-Cox) test, and a p-value <0.05 is considered
signiﬁcant.
GSE datasets were derived from Gene Expression Omnibus (GEO)
database. Wild-type animals in the GSE42742 dataset and breast cancer
patients in the GSE40640 dataset were employed for analysis. Signaling
network analysis was performed using the online tool GeneMANIA
(https://genemania.org/).20
Western Blot. Cells were cultured in 6-well plates and lysed at 50−
70% conﬂuency following the aforementioned procedures. The
concentrations of the resulting protein lysates were determined by
using the Bradford Assay (Bio-Rad). The whole-cell lysate for each
sample (10 μg) was denatured by boiling in Laemmli loading buﬀer and
resolved by using SDS-PAGE. Subsequently, the proteins were
transferred onto a nitrocellulose membrane at 4 °C overnight. The
resulting membrane was blocked with PBS-T (PBS with 0.1% Tween
20) containing 5% milk (Bio-Rad) at 4 °C for 6 h. The membrane was
subsequently incubated with primary antibody at 4 °C overnight and
then with secondary antibody at room temperature for 1 h. After
thorough washing with PBS-T, the HRP signal was detected using
Pierce ECL Western blotting substrate (Thermo).
Human HSPB8 antibody (Cell Signaling, no. 3059, 1:2000 dilution)
was employed as the primary antibody for Western blot analysis.
Horseradish peroxidase-conjugated anti-rabbit IgG was used as the
secondary antibody. Membranes were also probed with anti-actin
antibody (Cell Signaling, no. 4967, 1:10000 dilution) to verify equal
protein loading.
Real-Time PCR. Cells were seeded in 6-well plates at 50−70%
conﬂuence level. Total RNA was extracted from cells using TRI
Reagent (Sigma). Approximately 3 μg of RNA was reverse transcribed
by employing M-MLV reverse transcriptase (Promega) and an
oligo(dT)18 primer. After a 60 min incubation at 42 °C, the reverse
transcriptase was deactivated by heating at 75 °C for 5 min.
Quantitative real-time PCR was performed using iQ SYBR Green
Supermix kit (Bio-Rad) on a Bio-Rad iCycler system (Bio-Rad), and
the running conditions were at 95 °C for 3 min and 45 cycles at 95 °C
for 15 s, 55 °C for 30 s, and 72 °C for 45 s. The comparative cycle
threshold (Ct) method (ΔΔCt) was used for the relative quantiﬁcation
of gene expression,21 and the primer sequences are listed in Table S1.
■ RESULTS AND DISCUSSION
Quantitative Assessment of Diﬀerential Expression of
Heat Shock Proteins in Paired Radioresistant and
Parental Breast Cancer Cells. To explore the potential
roles of HSPs in developing radioresistance in breast cancer
cells, we utilized our recently developed PRM-based targeted
proteomic method,11 together with stable isotope labeling by
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amino acids in cell culture (SILAC)22 (Figure 1), to examine the
diﬀerential expression of HSPs in two pairs of breast cancer cells,
i.e., parental (WT) MCF-7 and the radioresistant C6 clone, and
WT MDA-MB-231 and the radio-resistant C5 clone.
Approximately 50% of the human HSPs (Figure 2 and Table
S2) were quantiﬁed with the PRM-based targeted proteomic
method. Speciﬁcally, 43 and 42 unique HSPs were quantiﬁed in
the MCF-7 WT/C6 and MDA-MB-231 WT/C5 paired cells,
respectively. All PRM transitions (4−6) used for each tryptic
peptide derived from HSPs displayed the same retention time,
with the dot product (dotp) value23 being >0.7 (Figure S1). In
addition, more than 90% of the quantiﬁed proteins appeared in
both forward and reverse SILAC labeling experiments (Figure
3a,b). Furthermore, the ratios of the quantiﬁed peptides
obtained from forward and reverse SILAC labeling experiments
exhibited an excellent linear ﬁt (Figure 3c,d). The results,
therefore, conﬁrmed the excellent reproducibility of our PRM
method.
Members of HSP70 and HSP40 Proteins Are Altered
upon the Development of Radioresistance in Breast
Cancer Cells. Figure 4 shows that 39 HSPs were commonly
quantiﬁed for the two pairs of radioresistant/parental breast
cancer cells. In addition, the relative expression of HSPs between
the two pairs of matched breast cancer cells exhibited similar
proﬁles (Figure 4b,c).Moreover, 8 HSPs (i.e., HSPA9, HSPA14,
HSPB8, HSPC125, DNAJA1, DNAJB1, DNAJC3, and
DNAJC7) were commonly altered in both lines of radioresistant
cells relative to the corresponding parental lines (Figures 4c and
5a). Furthermore, the relative mRNA expression of genes
encoding HSPA9, HSPA14, and HSPC125 were positively
correlated with the overall survival of breast cancer patients
undergoing radiation therapy, with higher mRNA levels of these
genes being associated with poorer overall survival (Figures 5b
and S2a,b). Along this line, both HSPA9 and HSPA14 belong to
the HSP70 subfamily, which was previously shown to be
associated with radioresistance in human glioma spheroids.24 In
addition, interrogation of several Gene Expression Omnibus
(GEO) datasets indicated that HSP70 was also correlated with
radiation sensitivity of breast cancer patients. The expression of
HSPA9 was increased for the mouse mammary glands after
ionizing radiation (IR) (GSE42742, n = 30, Figure S2c),25 while
elevated expression of HSP14 was observed in IR-resistant
breast cancer patients relative to IR-sensitive patients
(GSE40640, n = 32, Figure 5c).26,27 This result indicates that
HSPA9 and HSPA14 may promote the development of
radioresistance in breast cancer patients.
Aside from the 3 HSPs whose mRNA expression levels are
closely associated with patient survival, 4 out of 8 commonly
changed HSPs (DNAJA1, DNAJB1, DNAJC3, and DNAJC7)
belong to the HSP40 subfamily, and 3 were up-regulated in the
radioresistant cell lines (DNAJA1, DNAJB1, and DNAJC7). On
the grounds that HSP70 and HSP40 function together as a
chaperone complex,28,29 HSP40may assist HSP70 in promoting
the development of radioresistance. In this regard, DNAJA1
(a.k.a. HDJ2) and DNAJB1 (a.k.a. HDJ1), which are known to
be co-chaperones of HSP70,30 were up-regulated by ∼2-fold in
the two radioresistant breast cancer cell lines relative to the
corresponding parental lines (Figure 5d,e). In addition,
DNAJA1 was involved with radiosensitivity of glioblastoma
multiforme cells,31,32 and DNAJB1 was shown to sensitize lung
cancer cells to geﬁtinib through regulating the EGFR signaling
pathway.33 Along this line, the EGFR signaling pathway also
plays an important role in radioresistance of tumor cells.34,35
Together, the altered expression of these HSP70 and HSP40
proteins may contribute to radioresistance in breast cancer cells.
HSPB8 Is Up-Regulated in Radioresistant Breast
Cancer Cell Lines. HSPB8 exhibits a pronouncedly increased
expression (by ∼10-fold) in the radioresistant lines of both
MCF-7 and MDA-MB-231 cells (Figures 5a and 6a), and we
validated the up-regulation of HSPB8 by Western blot analysis
(Figure 6b,c). Meanwhile, the mRNA level of HSPB8 was also
elevated in the radioresistant line (Figure 6d), indicating that the
augmented expression of HSPB8 occurs through a transcrip-
tional mechanism.
HSPB8 is a member of small HSPs mediating the clearance of
misfolded proteins;36 thus, it can modulate the proliferation and
migration of breast cancer cells, including theMCF-7 andMDA-
MB-231 cells used in the present study.37 HSPB8 was also found
to promote drug resistance under many circumstances. For
instance, it is involved in the development of bortezomib
resistance in multiple myeloma cells,38 irinotecan resistance in
colorectal cancer cells,39 and tamoxifen resistance in breast
cancer cells.40 Furthermore, HSPB8 coordinates with HSP70-
BAG3 and functions as a chaperone complex,41 which is
modulated by NF-κB protein.42 Others have shown that NF-κB
could promote the development of radioresistance in both
MCF-7 and MDA-MB-231 cells.13 Thus, NF-κB may regulate
the HSPB8-HSP70-BAG3 complex in breast cancer cells and
modulate their radiosensitivity. Since the expression ofHSPB8 is
uniformly and markedly increased in both lines of radioresistant
breast cancer cells, HSPB8 could be critical in conferring the
development of radioresistance in breast cancer cells.
Signaling Network of HSPs in the Development of
Radioresistance. Since we have discovered that HSPs may
play important roles in radioresistance development, we next
explored the potential signaling networks involving those HSPs.
Previously, we found that a group of kinases were overexpressed
in radioresistant breast cancer cells, including checkpoint kinase
1 (CHK1), cyclin-dependent kinases 1 and 2 (CDK1 and
CDK2), and the catalytic subunit of DNA-dependent protein
kinase.43 These altered kinome proﬁles of radioresistant MCF-
7/C6 cells suggest the contributions of those kinases involved in
cell cycle progression and DNA repair to tumor-adaptive
Figure 1. General workﬂow for the scheduled LC-PRM analysis in the
quantitative assessment of the human heat shock proteome. Shown is a
ﬂowchart of the forward SILAC labeling and LC-PRM experiment.
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radioresistance. For instance, CHK1 was previously shown to
promote the development of radioresistance.44,45 In addition,
signaling network analysis (Figure S3) suggested that the altered
HSPs (HSPC125, a.k.a. NDUFAF4, DNAJB1, and HSPB8)
interact with the previously identiﬁed kinases (CHK1, CDK1,
and CDK2). Therefore, these kinases may coordinate with the
currently identiﬁed cluster of HSPs to form a prosurvival
network that confers radioresistance in breast cancer.
■ CONCLUSIONS
In this study, we employed our recently developed PRM-based
targeted proteomic method to examine the reprogramming of
the human heat shock proteome during the development of
radioresistance in breast cancer cells. We investigated the
diﬀerential expression of heat shock proteins (HSPs) in two
pairs of matched parental/radioresistant breast cancer cell lines.
We were able to quantify 43 and 42HSPs in theMCF-7 pair and
the MDA-MB-231 pair, respectively. By comparing the
commonly perturbed HSPs, we found that altered expressions
of several members of the HSP70 and HSP40 protein
subfamilies are accompanied with the development of radio-
resistance. In addition, HSPB8 is a target of NF-κB, which is a
transcription factor known to promote radioresistance and is
present at markedly elevated levels in both lines of radioresistant
breast cancer cells; thus, HSPB8 could be critical in the
development of radioresistance in breast cancer. In summary,
our PRM-based targeted proteomic method constitutes a
unique tool to examine the reprogramming of heat shock
proteome and reveals potential targets to sensitize cancer cells
toward radiation therapy.
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